文献速递脑血管病

机械取栓联合或不联合静脉溶栓的结局比较

Mechanical Thrombectomy Outcomes With or Without Intravenous Thrombolysis.
PubMed 文献 · Stroke · 2018-01-01

该研究为ASTER试验的事后分析,比较机械取栓前是否接受静脉溶栓对功能结局、神经功能恢复、再灌注及不良事件的影响。共纳入381例患者,其中250例接受静脉溶栓联合机械取栓。结果显示联合治疗组90天死亡率低于单纯取栓组(完全校正风险比0.59;95%CI 0.39-0.88),在卒中前未使用抗凝药的患者亚组中联合治疗还与更好的功能结局和再通率相关。

要点

  • 静脉溶栓联合机械取栓组90天死亡率低于单纯机械取栓组,完全校正风险比0.59(95%CI 0.39-0.88)。
  • 两组90天良好功能结局、成功再灌注率、24小时美国国立卫生研究院卒中量表评分改善及出血并发症率无显著差异。
  • 在卒中前未使用抗凝药的患者亚组中,联合治疗组功能结局更好(完全校正风险比1.38;95%CI 1.02-1.89),一线策略后再通率更高(完全校正风险比1.26;95%CI 1.05-1.50),死亡率更低(完全校正风险比0.58;95%CI 0.36-0.93)。

核心结论

  • ASTER试验中静脉溶栓联合机械取栓的患者90天死亡率低于单纯机械取栓的患者。
  • 在卒中前未使用抗凝药的选择性患者人群中,静脉溶栓联合机械取栓可能改善功能结局和再通率,同时降低死亡率。

研究设计与样本

  • 该研究为ASTER试验(接触抽吸与支架取栓器用于成功血管再通)的事后分析。
  • 共纳入381例患者,其中250例在机械取栓前接受了静脉溶栓(静脉溶栓联合机械取栓组)。

主要发现

  • 静脉溶栓联合机械取栓组与单纯机械取栓组在90天良好功能结局(改良Rankin量表≤2分)、成功再灌注率(改良脑梗死溶栓分级2b或3级)、24小时美国国立卫生研究院卒中量表评分改善及出血并发症率方面均无显著差异。
  • 静脉溶栓联合机械取栓组90天死亡率低于单纯机械取栓组,完全校正风险比0.59(95%CI 0.39-0.88)。
  • 在卒中前未使用抗凝药的患者亚组中,静脉溶栓联合机械取栓组功能结局更好(完全校正风险比1.38;95%CI 1.02-1.89),一线策略后成功再通率更高(完全校正风险比1.26;95%CI 1.05-1.50),死亡率更低(完全校正风险比0.58;95%CI 0.36-0.93)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Intravenous thrombolysis (IVT) within 4.5 hours of symptom onset is currently recommended before mechanical thrombectomy (MT). We compared functional outcome, neurological recovery, reperfusion, and adverse events according to the use or not of IVT before MT. Methods- This is a post hoc analysis of the ASTER trial (Contact Aspiration Versus Stent Retriever for Successful Revascularization). The primary outcome was favorable 90-day functional outcome defined as a modified Rankin Scale of ≤2. Secondary outcomes were successful reperfusion following all procedures and after the first-line procedure, number of device passes, and change in National Institutes of Health Stroke Scale score at 24 hours. Safety outcomes included 90-day mortality and any symptomatic intracerebral hemorrhage. Results- Three hundred eighty-one patients were included, 250 of whom received IVT before MT (IVT+MT group). There were no significant differences between IVT+MT and MT-alone groups in 90-day favorable functional outcome, in successful reperfusion rate (modified Thrombolysis In Cerebral Infarction 2b or 3), in National Institutes of Health Stroke Scale score improvement at 24 hours, or in hemorrhagic complication rate. The 90-day mortality rate in the IVT+MT group was lower than after MT alone (fully-adjusted risk ratio, 0.59; 95% CI, 0.39-0.88). In a subgroup of patients without anticoagulant medication before stroke onset, we observed in the IVT+MT group a better functional outcome (fully-adjusted risk ratio, 1.38; 95% CI, 1.02-1.89), a higher successful recanalization rate after first-line strategy (fully-adjusted risk ratio, 1.26; 95% CI, 1.05-1.50), and a lower mortality rate (fully-adjusted risk ratio, 0.58; 95% CI, 0.36-0.93). Conclusions- Our results show that IVT+MT patients in the ASTER trial have lower 90-day mortality compared with those receiving MT alone. In a selected population of patients without prestroke anticoagulation, we demonstrated that IVT associated with MT might improve functional outcome and recanalization while reducing mortality rates.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Gariel F, Lapergue B, Bourcier R, et al. Mechanical Thrombectomy Outcomes With or Without Intravenous Thrombolysis. Stroke. 2018. PMID: 30355117. doi:10.1161/STROKEAHA.118.021500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。